Abstract
The constitutively active serine/threonine kinase Pim-1 is upregulated in different cancer types, mainly based on the action of several interleukines and growth factors at the transcriptional level. So far, a regulation of oncogenic Pim-1 by microRNAs (miRNAs) has not been reported. Here, we newly establish miR-33a as a miRNA with potential tumor suppressor activity, acting through inhibition of Pim-1. A screen for miRNA expression in K562 lymphoma, LS174T colon carcinoma and several other cell lines revealed generally low endogenous miR-33a levels relative to other miRNAs. Transfection of K562 and LS174T cells with a miR-33a mimic reduced Pim-1 levels substantially. In contrast, the cell-cycle regulator cyclin-dependent kinase 6 predicted to be a conserved miR-33a target, was not downregulated by the miR-33a mimic. Seed mutagenesis of the Pim-1 3′-untranslated region in a luciferase reporter construct and in a Pim-1 cDNA expressed in Pim-1-deficient Skov-3 cells demonstrated specific and direct downregulation of Pim-1 by the miR-33a mimic. The persistence of this effect was comparable to that of a small interfering RNA-mediated knockdown of Pim-1, resulting in decelerated cell proliferation. In conclusion, we demonstrate the potential of miR-33a to act as a tumor suppressor miRNA, which suggests miR-33a replacement therapy through delivery of miR mimics as a novel therapeutic strategy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ . (2004). Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 571: 43–49.
Amaravadi R, Thompson CB . (2005). The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115: 2618–2624.
Aqeilan RI, Calin GA, Croce CM . (2010). miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 17: 215–220.
Bachmann M, Hennemann H, Xing PX, Hoffmann I, Möröy T . (2004). The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 279: 48319–48328.
Bachmann M, Möröy T . (2005). The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 37: 726–730.
Bartel DP . (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297. Review.
Bartel DP . (2009). MicroRNAs: target recognition and regulatory functions. Cell 136: 215–233. Review.
Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L et al. (2008). The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271–1277.
Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J . (2010). PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 95: 1004–1015. Review.
Brennecke J, Stark A, Russell RB, Cohen SM . (2005). Principles of microRNA-target recognition. PLoS Biol 3: e85.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. (2002). Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524–21559.
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999–3004.
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT et al. (2005a). Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179.
Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS . (2005b). Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 3: 443–451.
Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102: 13944–13949.
Croce CM . (2009). Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704–714. Review.
Crowell JA, Steele VE, Fay JR . (2007). Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 6: 2139–2148.
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231–241.
Esquela-Kerscher A, Slack FJ . (2006). Oncomirs -- microRNAs with a role in cancer. Nat Rev Cancer 6: 259–269. Review.
Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB . (2003). The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 17: 1841–1854.
Gangaraju VK, Lin H . (2009). MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 10: 116–125.
Garzon R, Calin GA, Croce CM . (2009). MicroRNAs in cancer. Annu Rev Med 60: 167–179.
Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP . (2007). MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27: 91–105.
Grünweller A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, Kurreck J . (2003). Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 31: 3185–3193.
Herrera-Merchan A, Cerrato C, Luengo G, Dominguez O, Piris MA, Serrano M et al. (2010). miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle 15: 3277–3285.
Huang J, Manning BD . (2009). A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 37: 217–222.
Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK, Aigner A et al. (2011). MiRNA replacement therapy through PEI-mediated in vivo delivery of miR-145 or miR-33a in colon carcinoma. Cancer Res (doi:10.1158/0008-5472.CAN-10-4645).
Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065–7070.
Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A et al. (2005). RAS is regulated by the let-7 microRNA family. Cell 120: 635–647.
Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005–1017.
Lewis BP, Burge CB, Bartel DP . (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15–20.
Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R . (2005). MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol 7: 719–723.
Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM et al. (2007). Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem 14: 2009–2023.
Meyerson M, Harlow E . (1994). Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 14: 2077–2086.
Mikkers H, Nawijn M, Allen J, Brouwers C, Verhoeven E, Jonkers J et al. (2004). Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 24: 6104–6115.
Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y . (1999). Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 274: 18659–18666.
Muraski JA, Rota M, Misao Y, Fransioli J, Cottage C, Gude N et al. (2007). Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med 13: 1467–1475.
Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE et al. (2010). MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328: 1566–1569.
Nawijn MC, Alendar A, Berns A . (2011). For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 11: 23–34. Review.
O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT . (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839–843.
Qian KC, Wang L, Hickey ER, Studts J, Barringer K, Peng C et al. (2005). Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 280: 6130–6137.
Rayner KJ, Suárez Y, Dávalos A, Parathath S, Fitzgerald ML, Tamehiro N et al. (2010). miR-33 contributes to the regulation of cholesterol homeostasis. Science 328: 1570–1573.
Rehwinkel J, Behm-Ansmant I, Gatfield D, Izaurralde E . (2005). A crucial role for GW182 and the DCP1:DCP2 decapping complex in miRNA-mediated gene silencing. RNA 11: 1640–1647.
Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N . (2008). Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58–63.
Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M et al. (2009). Regression of murine lung tumors by the let-7 microRNA. Oncogene 29: 1580–1587.
van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T et al. (1989). Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 56: 673–682.
Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU et al. (2007). Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+cells. Blood 109: 4399–4405.
Verbeek S, van Lohuizen M, van der Valk M, Domen J, Kraal G, Berns A . (1991). Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol Cell Biol 11: 1176–1179.
Wang HW, Noland C, Siridechadilok B, Taylor DW, Ma E, Felderer K et al. (2009). Structural insights into RNA processing by the human RISC-loading complex. Nat Struct Mol Biol 16: 1148–1153.
Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS . (2002). Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 1593: 45–55.
Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W et al. (2009). Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 52: 74–86.
Xie Y, Xu K, Dai B, Guo Z, Jiang T, Chen H et al. (2006). The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene 25: 70–78.
Yang ZZ, Tschopp O, Baudry A, Dümmler B, Hynx D, Hemmings BA . (2004). Physiological functions of protein kinase B/Akt. Biochem Soc Trans 32: 350–354. Review.
Zhang T, Zhang X, Ding K, Yang K, Zhang Z, Xu Y . (2010). PIM-1 gene RNA interference induces growth inhibition and apoptosis of prostate cancer cells and suppresses tumor progression in vivo. J Surg Oncol 101: 513–519.
Zhang W, Shay JW, Deisseroth A . (1993). Inactive p53 mutants may enhance the transcriptional activity of wild-type p53. Cancer Res 15: 4772–4775.
Zhang Y, Wang Z, Li X, Magnuson NS . (2008). Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 27: 4809–4481.
Zhang Y, Wang Z, Magnuson NS . (2007). Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res 5: 909–922.
Zippo A, De Robertis A, Serafini R, Oliviero S . (2007). PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 9: 932–944.
Acknowledgements
We thank Robert Prinz, Dorothee Hartmann, Dennis Streng, Meike Thomas and Heide Marika Genau for technical support. This study was supported by the Fritz Thyssen Stiftung (reference no. 10.06.1.186 to AG and RKH), the Deutsche Krebshilfe (reference no. 109260 to AG, RKH and AA, and reference no. 106992 to AA) and DFG Forschergruppe Nanohale (AI 24/6-1).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Thomas, M., Lange-Grünweller, K., Weirauch, U. et al. The proto-oncogene Pim-1 is a target of miR-33a. Oncogene 31, 918–928 (2012). https://doi.org/10.1038/onc.2011.278
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.278
Keywords
This article is cited by
-
mTORC1 suppresses PIM3 expression via miR-33 encoded by the SREBP loci
Scientific Reports (2017)
-
MicroRNA-33b inhibits tumor cell growth and is associated with prognosis in colorectal cancer patients
Clinical and Translational Oncology (2016)
-
Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks
Apoptosis (2016)
-
MicroRNA: a connecting road between apoptosis and cholesterol metabolism
Tumor Biology (2016)
-
Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo
BMC Cancer (2015)